IM Neostigmine for Accelerating Bladder Emptying After CS by Spinal Anesthesia

• Status: Not yet recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to evaluate the effectiveness of intramuscular (IM) 0.5 mg neostigmine for accelerating bladder emptying and preventing postoperative urine retention (POUR) after cesarean section (CS) performed under spinal anesthesia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Neostigmine

Criteria

Inclusion Criteria:

• Pregnant women undergoing elective CS under spinal anesthesia.

Exclusion Criteria:

• Age < 20 or > 35 years.

• Height < 150 or > 180 cm or body mass index (BMI) > 35 kg/m2.

• Active labor.

• Multifetal pregnancy.

• Fetal distress.

• Placenta previa.

• Vaginal bleeding or placental abruption.

• Medical conditions complicating or co-existing with pregnancy such as HELLP syndrome, thrombocytopenia, hepatic or renal impairment, cardiac disease or pulmonary edema or cyanosis.

• Urinary tract symptoms (frequency incontinence, enuresis. nocturia, hesitancy, urgency, weak stream, dysuria, and inability to empty the bladder fully).

• Contraindication for central neuraxial block.

• History of adverse reaction contraindications for Neostigmine.

• Refusal to undergo regional anesthesia.

• Surgical duration > 1 hour.

• Intraoperative significant bleeding (> 10% of blood volume).

• Any postoperative complications as eclampsia.